Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Gastroenterology
Published in: BMC Gastroenterology 1/2023

Open Access 01-12-2023 | Ulcerative Colitis | Research

Network meta-analysis on efficacy and safety of different biologics for ulcerative colitis

Authors: Xinqiao Chu, Yaning Biao, Chengjiang Liu, Yixin Zhang, Chenxu Liu, Ji-zheng Ma, Yufeng Guo, Yaru Gu

Published in: BMC Gastroenterology | Issue 1/2023

Login to get access

Abstract

Background

Therapeutic options for ulcerative colitis (UC) have increased since the introduction of biologics a few decades ago. Due to the wide range of biologics available, physicians have difficulty in selecting biologics and do not know how to balance the best drug between clinical efficacy and safety. This study aimed to compare the efficacy and safety of biologics in treating ulcerative colitis.

Methods

In this study, eight electronic databases (PubMed, Web of Science, Cochrane, Embase, Sinomed, China National Knowledge Infrastructure, Chongqing VIP Information, and WanFang Data) were searched to collect eligible studies without language restrictions. Retrieved 1 June 2023, from inception. All articles included in the mesh analysis are randomised controlled trials (RCTs). The inclusion of drugs for each outcome was ranked using a curved surface under cumulative ranking (SUCRA). Higher SUCRA scores were associated with better outcomes, whereas lower SUCRA scores were associated with better safety. This study has registered with PROSPERO, CRD42023389483.

Results

Induction Therapy: Among the biologic therapies evaluated for induction therapy, vedolizumab demonstrated the highest efficacy in achieving clinical remission (OR vs daclizumab, 9.09; 95% CI, 1.01–81.61; SUCRA 94.1) and clinical response. Guselkumab showed the lowest risk of recurrence of UC (SUCRA 94.9%), adverse events resulting in treatment discontinuation (SUCRA 94.8%), and serious infections (SUCRA 78.0%). Maintenance Therapy: For maintenance therapy, vedolizumab ranked highest in maintaining clinical remission (OR vs mesalazine 4.36; 95% CI, 1.65–11.49; SUCRA 89.7) and endoscopic improvement (SUCRA 92.6). Infliximab demonstrated the highest efficacy in endoscopic improvement (SUCRA 92.6%). Ustekinumab had the lowest risk of infections (SUCRA 92.9%), serious adverse events (SUCRA 91.3%), and serious infections (SUCRA 67.6%).

Conclusion

Our network meta-analysis suggests that vedolizumab is the most effective biologic therapy for inducing and maintaining clinical remission in UC patients. Guselkumab shows promise in reducing the risk of recurrence and adverse events during induction therapy. Infliximab is effective in improving endoscopic outcomes during maintenance therapy. Ustekinumab appears to have a favorable safety profile. These findings provide valuable insights for clinicians in selecting the most appropriate biologic therapy for UC patients.
Appendix
Available only for authorised users
Literature
1.
Bisgaard TH, Allin KH, Keefer L, Ananthakrishnan AN, Jess T. Depression and anxiety in inflammatory bowel disease: epidemiology, mechanisms and treatment. Nat Rev Gastro Hepat. 2022;19(11):717–26.
2.
Zeng Z, Zhu Z, Yang Y, Ruan W, Peng X, Su Y, Peng L, Chen J, Yin Q, Zhao C, et al. Incidence and clinical characteristics of inflammatory bowel disease in a developed region of Guangdong Province, China: a prospective population-based study. J Gastroen Hepatol. 2013;28(7):1148–53.
3.
Hammer T, Nielsen KR, Munkholm P, Burisch J, Lynge E. The Faroese IBD Study: Incidence of Inflammatory Bowel Diseases Across 54 Years of Population-based Data. J Crohns Colitis. 2016;10(8):934–42.PubMedPubMedCentral
4.
Buie MJ, Quan J, Windsor JW, Coward S, Hansen TM, King JA, Kotze PG, Gearry RB, Ng SC, Mak J, et al. Global Hospitalization Trends for Crohn's Disease and Ulcerative Colitis in the 21st Century: A Systematic Review With Temporal Analyses. Clin Gastroenterol H. 2022;2211–21.
5.
Estevinho MM, Leao MP, Silva I, Laranjeira CJ, Santiago M, Magro F. A scoping review on early inflammatory bowel disease: definitions, pathogenesis, and impact on clinical outcomes. Ther Adv Gastroenter. 2022;15:1098325649.
6.
Na SY, Choi CH, Song EM, Bang KB. Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis. Intest Res. 2022;21(1):61–87.PubMedPubMedCentral
7.
Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer M, Parkes GC, Selinger C, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1–106.
8.
Thorlund K, Druyts E, Toor K, Mills EJ. Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs. Expert Rev Gastroent. 2015;9(5):693–700.
9.
Gisbert JP, Parody-Rua E, Chaparro M. Efficacy, Effectiveness, and Safety of Ustekinumab for the Treatment of Ulcerative Colitis: A Systematic Review. Inflamm Bowel Dis. 2023;izac275.
10.
Vieujean S, Louis E, Danese S, Peyrin-Biroulet L. A critical review of ustekinumab for the treatment of active ulcerative colitis in adults. Expert Rev Gastroent. 2023;17(5):413–30.
11.
Moens A, Alsoud D, Verstockt B, Sabino J, Ferrante M, Vermeire S. Adalimumab versus ustekinumab as first-line biological in moderate-to-severe Crohn’s disease: real-life cohort from a tertiary referral center. Eur J Gastroen Hepat. 2022;34(10):1015–20.
12.
Dalal RS, Mcclure EL, Marcus J, Allegretti JR. Comparative Long-Term Drug Survival of Vedolizumab, Adalimumab, and Infliximab in Biologic-Naive Patients with Ulcerative Colitis. Digest Dis Sci. 2023;68(1):223–32.PubMed
13.
Colombel JF, Sandborn WJ, Ghosh S, Wolf DC. Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3. Am J Gastroenterol. 2014;109(11):1771–80.PubMed
14.
Jarnerot G, Hertervig E, Friis-Liby I, Blomquist L. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;128(7):1805–11.PubMed
15.
Parikh A, Leach T, Wyant T, Scholz C. Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis. 2012;18(8):1470–9.PubMed
16.
Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777–84.PubMed
17.
Sands BE, Sandborn WJ, Panaccione R, O’Brien CD. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. New Engl J Med. 2019;381(13):1201–14.
18.
Feagan BG, Sands BE, Sandborn WJ, Germinaro M, Vetter M, Shao J, Sheng S, Johanns J, Panes J. Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial. Lancet Gastroenterol. 2023;8(4):307–20.
19.
Wan XM, Zhou XL, Zhang Z, Zheng JH. Clinical analysis of 28 cases of the moderate-to-severe ulcerative colitis treated with adamuzumab. Sichuan Med J. 2022;43:44–7.
20.
Vermeire S, Lakatos PL, Ritter T, Hanauer S. Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study. Lancet Gastroenterol. 2022;7(1):28–37.
21.
Rubin DT, Dotan I, Duvall A, Bouhnik Y. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials. Lancet Gastroenterol. 2022;7(1):17–27.
22.
Peyrin-Biroulet L, Hart A, Bossuyt P, Long M. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. Lancet Gastroenterol. 2022;7(2):128–40.
23.
Nagahori M, Watanabe K, Motoya S, Ogata H. Week 2 Symptomatic Response with Vedolizumab as a Predictive Factor in Japanese Anti-TNFalpha-Naive Patients with Ulcerative Colitis: A post hoc Analysis of a Randomized, Placebo-Controlled Phase 3 Trial. Digestion. 2021;102(5):742–52.PubMed
24.
Kobayashi T, Ito H, Ashida T, Yokoyama T. Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis. Intest Res. 2021;19(4):448–60.PubMed
25.
Sandborn WJ, Baert F, Danese S, Krznaric Z. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. Gastroenterology. 2020;158(3):562–72.PubMed
26.
Panaccione R, Danese S, Sandborn WJ, O’Brien CD. Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy. Aliment Pharm Ther. 2020;52(11–12):1658–75.
27.
Atreya R, Peyrin-Biroulet L, Klymenko A, Augustyn M. Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial. Lancet Gastroenterol. 2020;5(12):1063–75.
28.
Chen BL, Qian JM,Wu KC, et al. The safety and efficacy of infliximab in patients with active ulcerative colitis in China. Chin J Inflamm Bowel Dis. 2017:20–21.
29.
Vermeire S, Sandborn WJ, Danese S, Hebuterne X. Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10090):135–44.PubMed
30.
Sandborn WJ, Colombel JF, Ghosh S, Sands BE. Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study. J Crohns Colitis. 2016;10(4):418–28.PubMed
31.
Rutgeerts P, Feagan BG, Marano CW, Padgett L. Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis. Aliment Pharm Ther. 2015;42(5):504–14.
32.
Suzuki Y, Motoya S, Hanai H, Matsumoto T. Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis. J Gastroenterol. 2014;49(2):283–94.PubMed
33.
Sandborn WJ, Feagan BG, Marano C, Zhang H. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146(1):85–95 quiz e14- quiz e15.PubMed
34.
Panaccione R, Ghosh S, Middleton S, Marquez JR. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146(2):392–400.PubMed
35.
Mayer L, Sandborn WJ, Stepanov Y, Geboes K. Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. Gut. 2014;63(3):442–50.PubMed
36.
Sandborn WJ, Feagan BG, Marano C, Zhang H. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146(1):96–109.PubMed
37.
Sands BE, Sandborn WJ, Creed TJ, Dayan CM. Basiliximab does not increase efficacy of corticosteroids in patients with steroid-refractory ulcerative colitis. Gastroenterology. 2012;143(2):356–64.PubMed
38.
Sandborn WJ, van Assche G, Reinisch W, Colombel JF. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142(2):257–65.PubMed
39.
Sandborn WJ, Colombel JF, Frankel M, Hommes D. Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis. Gut. 2010;59(11):1485–92.PubMed
40.
Van Assche G, Sandborn WJ, Feagan BG, Salzberg BA, Silvers D, Monroe PS, Pandak WM, Anderson FH, Valentine JF, Wild GE, et al. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial. Gut. 2006;55(11):1568–74.PubMedPubMedCentral
41.
Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W. Infliximab for induction and maintenance therapy for ulcerative colitis. New Engl J Med. 2005;353(23):2462–76.PubMed
42.
Probert CS, Hearing SD, Schreiber S, Kuhbacher T, Ghosh S, Arnott ID, Forbes A. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut. 2003;52(7):998–1002.PubMedPubMedCentral
43.
Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009;330(3):864–75.PubMed
44.
Imazu N, Torisu T, Ihara Y, Umeno J, Kawasaki K, Fujioka S, Fuyuno Y, Matsuno Y, Moriyama T, Kitazono T. Ustekinumab Decreases Circulating Th17 Cells in Ulcerative Colitis. Internal Med. 2023;1724–23.
45.
Pugliese D, Privitera G, Fiorani M, Parisio L, Calvez V, Papa A, Gasbarrini A, Armuzzi A. Targeting IL12/23 in ulcerative colitis: update on the role of ustekinumab. Ther Adv Gastroenter. 2022;15:1098285259.
46.
Sands BE, Peyrin-Biroulet L, Loftus EJ, Danese S, Colombel JF, Toruner M, Jonaitis L, Abhyankar B, Chen J, Rogers R, et al. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. New Engl J Med. 2019;381(13):1215–26.PubMed
47.
Peyrin-Biroulet L, Arkkila P, Armuzzi A, Danese S, Guardiola J, Jahnsen J, Lees C, Louis E, Lukas M, Reinisch W, et al. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis. Bmc Gastroenterol. 2022;22(1):291.PubMedPubMedCentral
48.
Sablich R, Urbano MT, Scarpa M, Scognamiglio F, Paviotti A, Savarino E. Vedolizumab is superior to infliximab in biologic naive patients with ulcerative colitis. Sci Rep-Uk. 2023;13(1):1816.
49.
Welty M, Mesana L, Padhiar A, Naessens D, Diels J, van Sanden S, Pacou M. Efficacy of ustekinumab vs. advanced therapies for the treatment of moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Curr Med Res Opin. 2020;36(4):595–606.PubMed
Metadata
Title
Network meta-analysis on efficacy and safety of different biologics for ulcerative colitis
Authors
Xinqiao Chu
Yaning Biao
Chengjiang Liu
Yixin Zhang
Chenxu Liu
Ji-zheng Ma
Yufeng Guo
Yaru Gu
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2023
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-023-02938-6

Other articles of this Issue 1/2023

BMC Gastroenterology 1/2023 Go to the issue

Research

A study on prevention of bleeding complications using lusutrombopag for safe RFA in patients with hepatocellular carcinoma with low platelet counts: prospective observational study

Research

The comparison of an accessible C-shaped partial stapled hemorrhoidopexy (C-PSH) versus circular stapled hemorrhoidopexy (CSH) in patients with grade IV hemorrhoids: a retrospective cohort study

Research

HBV pregenome RNA as a predictor of spontanous HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients

Research

Effectiveness of betadine-coating gastrostomy tube to reduce peristomal infection after percutaneous endoscopic gastrostomy: a randomized controlled trial

Research article

Analysis of related factors of portal vein thrombosis in liver cirrhosis

Research

Gastrointestinal functioning and menstrual cycle phase in emerging young adult women: a cross-sectional study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits